-
2-HOBA in Systemic Lupus Erythematosus
NCT07225543 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: Female · 1 location
-
A Clinical Study of CD19 CAR-T in Active Systemic Lupus Erythematosus
NCT06106906 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Study of CD19 Universal CAR-γδT Cells in Active Systemic Lupus Erythematosus
NCT06106893 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Clinical Trial on the Efficacy and Safety of TQH3906 in the Treatment of Systemic Lupus Erythematosus
NCT07509892 ·
Phase: Phase 2 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female) · 35 locations
-
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus
NCT07260877 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 32 locations
-
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 19 locations
-
A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE/CLE Participants
NCT06625671 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 7 locations
-
A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)
NCT07564596 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
NCT06570798 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 58 locations
-
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205 ·
Phase: Phase 2 ·
Ages: 16 Years and older ·
Sex: All (male and female) · 2 locations
-
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT07570862 ·
Phase: Phase 2 ·
Ages: 12 Years to 70 Years ·
Sex: All (male and female) · 9 locations
-
A Phase II Clinical Study on the Efficacy and Safety of SHR-2173 Injection in the Treatment of Patients With Active Lupus Nephritis
NCT07229742 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Phase IIa Study of ICG318 CAR-T in Refractory Systemic Lupus Erythematosus With or Without Lupus Nephritis
NCT07328581 ·
Phase: Phase 2 ·
Ages: 16 Years to 70 Years ·
Sex: All (male and female) · 4 locations
-
A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus.
NCT06182969 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: Female · 1 location
-
A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)
NCT07311200 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
A Study of E6742 in Participants With Systemic Lupus Erythematosus
NCT07515014 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 54 locations
-
A Study of GR1803 in Systemic Lupus Erythematosus
NCT07348055 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 60 Years ·
Sex: All (male and female) · 1 location
-
A Study of IMC-002 for the Treatment of Active Systemic Lupus Erythematosus
NCT06535412 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
A Study of Quinacrine in Participants With Cutaneous Lupus Erythematosus
NCT07694336 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
NCT06581198 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 101 locations
-
A Study of SCTB35 in Patients with Systemic Lupus Erythematosus
NCT06841042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 14 locations
-
A Study of SHR-2173 in Participants With Systemic Lupus Erythematosus
NCT07299422 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
A Study of Telitacicept in Lupus Nephritis
NCT05680480 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 45 locations
-
A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis
NCT07598396 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 21 locations
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Obinutuzumab in Adolescents With Active Class III or IV Lupus Nephritis and the Safety and PK of Obinutuzumab in Pediatric Participants
NCT05039619 ·
Phase: Phase 2 ·
Ages: 5 Years to 17 Years ·
Sex: All (male and female) · 43 locations
-
A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With Rituximab Injection Versus Placebo in Patients With Active Glomerulonephritis
NCT07038382 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 17 locations
-
A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE
NCT06897930 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 20 locations
-
A Study to Test Whether Different Doses of BI 3000202 Help People With Systemic Lupus Erythematosus (SLE)
NCT07409181 ·
Phase: Phase 2 ·
Ages: 18 Years to 74 Years ·
Sex: All (male and female) · 140 locations
-
Anti-CD19 CAR T-Cell Therapy in Refractory Systemic Autoimmune Diseases
NCT06685042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Systemic Lupus Erythematosus
NCT06585514 ·
Phase: Phase 1, Phase 2 ·
Ages: 3 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Autologous Stem Cell Transplant (ASCT) for Autoimmune Diseases
NCT05029336 ·
Phase: Phase 2 ·
Ages: 8 Years to 25 Years ·
Sex: All (male and female) · 1 location
-
BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
NCT06794008 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 2 locations
-
CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
NCT06347718 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH
NCT06947460 ·
Phase: Phase 1, Phase 2 ·
Ages: 10 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
CD19-Directed Chimeric Antigen Receptor Autologous T Cells (CART19) for Lupus
NCT06839976 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years to 29 Years ·
Sex: All (male and female) · 1 location
-
COVID-19 Booster and IIV Schedule in Immunocompromised Hosts
NCT06599658 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
Descartes-08 for Children, Adolescents, and Young Adults With Autoimmune Disorders
NCT07089121 ·
Phase: Phase 1, Phase 2 ·
Ages: 12 Years and older ·
Sex: All (male and female) · 3 locations
-
Double-blind Placebo Controlled Study to Evaluate the Effect of NAD+ Boosting With Nicotinamide Riboside on Immunometabolism and Immunity in Systemic Lupus Erythematosus
NCT06032923 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 120 Years ·
Sex: Female · 1 location
-
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
NCT05508009 ·
Phase: Phase 1, Phase 2 ·
Ages: 1 Year to 30 Years ·
Sex: All (male and female) · 1 location
-
Evaluate the Efficacy and Safety of ICP-488 in Subjects With Cutaneous Lupus Erythematosus (CLE) Double-blind Study
NCT07440537 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 27 locations
-
Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus
NCT05688696 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 41 locations
-
FT839 in Autoimmune Diseases
NCT07800871 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
Fourth-gen CAR T Cells Targeting BCMA/CD19 for Refractory Systemic Lupus Erythematosus (SLE)
NCT06350110 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
IMPACT Study: IMProve Pregnancy in APS With Certolizumab Therapy
NCT03152058 ·
Phase: Phase 2 ·
Ages: 18 Years to 40 Years ·
Sex: Female · 3 locations
-
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07138898 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
JY231 Injection for the Treatment of Active Systemic Lupus Erythematosus (SLE)
NCT06675422 ·
Phase: Phase 1, Phase 2 ·
Ages: 14 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
MB-CART19.1 in Refractory SLE
NCT06189157 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 3 locations
-
Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
NCT07053800 ·
Phase: Phase 2 ·
Ages: 12 Years to 65 Years ·
Sex: All (male and female) · 15 locations
-
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
NCT06434363 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
Phase IIa Study for IPG11406 in Patients With Lupus Nephritis
NCT06717815 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 17 locations
-
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
NCT06121297 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 23 locations
-
RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
NCT06058078 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus
NCT07523542 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
SGLT2 Inhibitor in Lupus Nephritis Patients With Chronic Kidney Disease
NCT06155604 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Safety and Efficacy of Universal CD19-targeting CAR-γδT Cells in Refractory Autoimmune Diseases
NCT06828042 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
Safety of Administering Isoniazid to SLE Patients to Prevent TB
NCT06618573 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 55 Years ·
Sex: Female · 1 location
-
Sequential CAR-T Cells Targeting BCMA/CD19 in Patients With Relapsed/ Refractory Autoimmune Diseases
NCT06428188 ·
Phase: Phase 1, Phase 2 ·
Ages: 21 Years to 90 Years ·
Sex: All (male and female) · 1 location
-
Sirolimus in Patients With Systemic Lupus Erythematosus-Associated Immune Thrombocytopenia
NCT07657793 ·
Phase: Phase 2, Phase 3 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289 ·
Phase: Phase 2 ·
Ages: 18 Years to 100 Years ·
Sex: All (male and female) · 103 locations
-
Study of YK012 in Moderate to Severe Systemic Lupus Erythematosus
NCT07010835 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
Study to Assess Efficacy and Safety of HSK39297 Tablets in Patients With LN
NCT07363460 ·
Phase: Phase 2 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female) · 1 location
-
Study to Evaluate the Efficacy of Ruxolitinib 1.5% Cream in Adult Subjects with Discoid Lupus Erythematosus
NCT06261021 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 2 locations
-
The Efficacy and Safety of Biologics (Belimumab/ Telitacicept) Induction Therapy in Proliferative Lupus Nephritis Patients for 6 Months Compared With Mycophenolate Mofetil Treatment
NCT07340463 ·
Phase: Phase 2 ·
Ages: 14 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
NCT05538208 ·
Phase: Phase 2 ·
Ages: 8 Years to 20 Years ·
Sex: All (male and female) · 19 locations
-
The Purpose of This Study is to Evaluate the Efficacy and Safety of 626 in the Treatment of SLE
NCT07185269 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 1 location
-
The Role of Anifrolumab in Improving Markers of Vascular Risk in Patients With Systemic Lupus Erythematosus (SLE) - IFN-CVD
NCT05440422 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female) · 1 location
-
To Evaluate the Efficacy and Safety of SG301 SC Injection in Systemic Lupus Erythematosus
NCT07447986 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female) · 40 locations
-
Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
NCT03673748 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 1 location
-
Treatment of Systemic Lupus Erythematosus With Human Umbilical Cord Mesenchymal Stem Cells
NCT07041801 ·
Phase: Phase 1, Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
NCT06947473 ·
Phase: Phase 1, Phase 2 ·
Ages: 6 Years to 65 Years ·
Sex: All (male and female) · 1 location
-
VIBRANT: VIB4920 for Active Lupus Nephritis
NCT05201469 ·
Phase: Phase 2 ·
Ages: 18 Years and older ·
Sex: All (male and female) · 17 locations